AcelRx Pharmaceuticals, Inc. (ACRX)
-NasdaqGM 7.86 
0.41(5.50%) May 24, 4:00PM EDT|After Hours
:
7.85 0.01 (0.13%) May 24, 5:48PM EDT
| Prev Close: | 7.45 |
|---|
| Open: | 7.51 |
|---|
| Bid: | 5.71 x 1700 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 10.43 |
|---|
| Beta: | 1.63 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 7.36 - 8.02 |
|---|
| 52wk Range: | 2.27 - 8.02 |
|---|
| Volume: | 568,136 |
|---|
| Avg Vol (3m): | 356,934 |
|---|
| Market Cap: | 292.68M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- This Week in Biotechat Motley Fool(Sat, May 25)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, May 21)
- Why AcelRx Pharmaceuticals Shares Spiked Temporarilyat Motley Fool(Tue, May 21)
- AcelRx pain treatment meets late-stage study goalsAP(Tue, May 21)
- Home Deport gains on strong resultsoptionMONSTER(Tue, May 21)
- AcelRx announces positive results from Phase 3 study of Sufentanil PCA systemat theflyonthewall.com(Tue, May 21)
- Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative PainPR Newswire(Tue, May 21)
- AcelRx Pharmaceuticals to Present at the UBS Global Healthcare ConferencePR Newswire(Thu, May 16)
- ACELRX PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 14)
- ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExEDGAR Online(Fri, May 10)
- ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, May 9)
- AcelRx Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- AcelRx Pharmaceuticals Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 8)
- ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Q1 2013 AcelRx Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 92.32 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.96 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain.
View More